Metered dose inhalers: current and future uses

British Journal of Clinical Practice

Volumn , Issue SUPPL. 89, 1997, Pages 16-21

  Levy, M L ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; HUMAN; NEBULIZER;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; NEBULIZERS AND VAPORIZERS;

EID: 0031129710     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Royal College of General Practitioners, Office of Population Censuses and Surveys. Morbidity statistics from general practice 1981-82. Third national study. Department of Health and Social Security, HMSO: London, 1986; 49-50.
2. British Lung Foundation. The Lung Report. Lung disease: a shadow over the nation's health. British Lung Foundation: London, 1996.
3. Central Health Monitoring Unit. In: Asthma: an epidemiological overview. Department of Health, HMSO: London, 1995.
4. Department of Public Health Sciences. Trends for hospital admissions for asthma. Lung and Asthma Information Agency (LAIA) 1996; Fact Sheet 96/2.
5. Department of Public Health Sciences. The geography of COPD mortality in the elderly. Lung and Asthma Information Agency (LAIA)'l 9%; Fact Sheet 96/1.
6. Anonymous. Monthly index of medical specialities (M1MS}. February 1997:232 233.
7. IMS Medical Data index Vol 3; Quarter 4 1995.
8. Idris AH, McDermott MF, Raucci JC el al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebuliser. Chest 1993; 103: 665-672.
9. Kish GL, Paloucek FP. Metered-dose inhalers and nebulisers in ihe acute setting. Ann rhartnuct therdyp 1992; 26: 92-95.
10. Woodman K, Bremner P, Burgess C et al. A comparative study of the etïicac of beclomethasone dipropionate delivered from a breath activated and conventional metered dose inhaler in asthmatic patients. Curr Meu Res Opin 1993; 2: 61 69.
11. l.Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest 1994; 106: 462 465.
12. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderl subjects. Chest 1993; 104: 1332 1337.
13. Bronsky EA, Debelic M, Pujet JC, Hahn M. Ease of use study of pirbuterol acetate in ihe Autohaler actuator in three countries: the United States, Germany and France. J Asthma 1993; 39: 439 443.
14. Levy ML, Hilton SR. Asthma in Practice. Royal College General Practitioners: London 1993; 116.
15. Bisgaard H. A metal aerosol holding chamber devised lor young children with asthma. Eitr Resp J 1995; 8: 856-860.
16. O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer by use of an antistatic lining, immediate inhalation and avoiding multiple actuations of drug. Thorax 1993; 48: 603-606.
17. Barry PW, O'Callaghan C. Poor output of salbutamol from a spacer device: effect of spacer static charge and multiple actuations. Thorax 1994;49:402.
18. O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation? Thorax 1994; 49: 961-964.
19. Barry PW, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Resp J 1994; 7: 1707-1709.
20. Miller MR, Bright P. Differences in output from corticosleroid inhalers with a Volumatic spacer. £nr 1995; 8(10): 1637 1638.
21. 1 .Kenyon CJ, Dewsbury NJ, Newman SP. Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacer. Thorax 1995; 50(8): 846-850.
22. Tansey I. The technological development of Airomir (salbutamol sulphate in CFC-free system) MDI. Brit.I Clin Print 1995; Suppl 79: 13-17.
23. Kleerup L:C, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered dose inhaler in patients with asthma. Chest 1996; 109: 702 707.
24. Salat D, Popov D, Stuart AM. Switching treatment from CFC salbutamol to CFC-free salbutamol: a controlled clinical trial [Abstract]. Eur Resp J 1996; 9(SuppI 23): 256s.
25. Baumgarten C. Kettner J, Sykes AP. Safety and efficacy of salbutamol lOOug prn via a pressurised inhaler formulated with a new CFC-free propellant GR 106642X [Abstract]. Eur Resp J 1995; 8(Suppl 19): 157s.
26. Ayres J. Millar A, Williams F. Efficacy and safety of tluticasone propionate 2mg daily administered with a new CFC-propellant GR 106642X [Abstract). Am J Resp Crit Care Med 1995; 151: A61.
27. Bateman E, Ringdal N, I.aitinen I,A, Sykes AP. Safety and efficacy of salmeterol 50ug bid via a pressurised inhaler formulated w ith a new CFC-free propellant, GR I06642X [Abstract]. J Aerosol Mnl 1995; 8: 88.
28. Leach C'. Enhanced drug delivery through reformulating MDIs with HFA propellants: Drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, Eds. Respiruttr Drug DeliverV Proeeedings. Interpharm Press 1996; 133 144.
29. Siafakas NM, Vermiere NB, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Resp J 1995; 8(8): 1398-1420.